Selected minor cannabinoids in attention-deficit/hyperactivity disorder: a translational scoping review of neuropharmacological mechanisms and research priorities

Background Minor phytocannabinoids have pharmacological profiles distinct from Δ9-tetrahydrocannabinol and cannabidiol, but their potential relevance to attention-deficit/hyperactivity disorder (ADHD) remains poorly defined. Cannabigerol (CBG), cannabidivarin (CBDV), and tetrahydrocannabivarin (THCV) interact with molecular targets and neural systems implicated in attention, inhibitory control, reward processing, and catecholaminergic signaling. Methods We conducted a translational scoping review following JBI methodological guidance and PRISMA-ScR reporting principles. PubMed, PsycINFO, Web of Science, and Scopus were searched on 1 August 2026. After duplicate removal, 1,066 records underwent title/abstract screening independently by two reviewers, and 179 proceeded to full-text assessment. Backward reference-list screening and forward citation tracking complemented database retrieval. Eighty-three eligible reports corresponding to 81 unique studies were included. Results Evidence supported distinct translational profiles rather than a common “minor cannabinoid” mechanism. CBG showed the most direct convergence with ADHD-relevant catecholaminergic pharmacology, particularly α2-adrenoceptor and locus-coeruleus mechanisms, alongside human pharmacokinetic data and preliminary direct ADHD evidence from a non-peer-reviewed doctoral dissertation. CBDV showed convergence around TRPV1 signaling, excitation–inhibition balance, and striatal target engagement, but no direct ADHD efficacy evidence. THCV demonstrated context-, ligand-, and isomer-dependent CB1/CB2 pharmacology, controlled human neural evidence, and selected pharmacokinetic and safety data, but no ADHD trial. ADHD–ECS findings were heterogeneous and sometimes directionally opposing, supporting selective remodeling rather than uniform alteration of endocannabinoid signaling. Conclusion Current evidence supports compound-specific neuropharmacological hypotheses, not established treatment efficacy for ADHD. CBG warrants rigorous peer-reviewed replication integrating dose–exposure relationships and cognitive safety; CBDV warrants ADHD-specific target-engagement studies before efficacy testing; and THCV requires isomer-specific mechanistic and psychiatric/cognitive-safety evaluation.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-17
DOI
https://doi.org/10.3389/fphar.2026.1978737
Primary Topic
Cannabis and Cannabinoid Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Selected minor cannabinoids in attention-deficit/hyperactivity disorder: a translational scoping review of neuropharmacological mechanisms and research priorities

Maria Gabriela Costa Ribeiro, Katy Lísias Gondim Dias de Albuquerque, Beatriz Araújo Pessoa, Wilsonda da Silva Lessa Júnior
1 links
Frontiers in Pharmacology
Cannabis and Cannabinoid Research
article

Selected minor cannabinoids in attention-deficit/hyperactivity disorder: a translational scoping review of neuropharmacological mechanisms and research priorities

Maria Gabriela Costa Ribeiro, Katy Lísias Gondim Dias de Albuquerque, Beatriz Araújo Pessoa, Wilsonda da Silva Lessa Júnior
article en

Abstract

Background Minor phytocannabinoids have pharmacological profiles distinct from Δ9-tetrahydrocannabinol and cannabidiol, but their potential relevance to attention-deficit/hyperactivity disorder (ADHD) remains poorly defined. Cannabigerol (CBG), cannabidivarin (CBDV), and tetrahydrocannabivarin (THCV) interact with molecular targets and neural systems implicated in attention, inhibitory control, reward processing, and catecholaminergic signaling. Methods We conducted a translational scoping review following JBI methodological guidance and PRISMA-ScR reporting principles. PubMed, PsycINFO, Web of Science, and Scopus were searched on 1 August 2026. After duplicate removal, 1,066 records underwent title/abstract screening independently by two reviewers, and 179 proceeded to full-text assessment. Backward reference-list screening and forward citation tracking complemented database retrieval. Eighty-three eligible reports corresponding to 81 unique studies were included. Results Evidence supported distinct translational profiles rather than a common “minor cannabinoid” mechanism. CBG showed the most direct convergence with ADHD-relevant catecholaminergic pharmacology, particularly α2-adrenoceptor and locus-coeruleus mechanisms, alongside human pharmacokinetic data and preliminary direct ADHD evidence from a non-peer-reviewed doctoral dissertation. CBDV showed convergence around TRPV1 signaling, excitation–inhibition balance, and striatal target engagement, but no direct ADHD efficacy evidence. THCV demonstrated context-, ligand-, and isomer-dependent CB1/CB2 pharmacology, controlled human neural evidence, and selected pharmacokinetic and safety data, but no ADHD trial. ADHD–ECS findings were heterogeneous and sometimes directionally opposing, supporting selective remodeling rather than uniform alteration of endocannabinoid signaling. Conclusion Current evidence supports compound-specific neuropharmacological hypotheses, not established treatment efficacy for ADHD. CBG warrants rigorous peer-reviewed replication integrating dose–exposure relationships and cognitive safety; CBDV warrants ADHD-specific target-engagement studies before efficacy testing; and THCV requires isomer-specific mechanistic and psychiatric/cognitive-safety evaluation.

Frontiers in PharmacologyVol. 17
Universidade Federal da Paraíba (BR)
Good health and well-being
Cannabis and Cannabinoid Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon